KEAP1 and cancer: In concordance with these previous results, our results demonstrated that downregulation of the Nrf2 expression in Keap1 mutated cancer cells or introduction of Keap1 cDNA in Keap1 mutant cells significantly enhances the sensitivity to cisplatin.